Literature DB >> 33482592

Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer.

Xianfeng Wang1, Thomas Hielscher2, Jan Philipp Radtke3, Magdalena Görtz4, Viktoria Schütz4, Tristan Anselm Kuder5, Regula Gnirs6, Constantin Schwab7, Albrecht Stenzinger7, Markus Hohenfellner4, Heinz-Peter Schlemmer8, David Bonekamp9.   

Abstract

BACKGROUND: Mean ADC has high predictive value for the presence of clinically significant prostate cancer (sPC). Measurement variability is introduced by different scanners, protocols, intra-and inter-patient variation. Internal calibration by ADC ratios can address such fluctuations however can potentially lower the biological value of quantitative ADC determination by being sensitive to deviations in reference tissue signal.
PURPOSE: To better understand the predictive value of quantitative ADC measurements in comparison to internal reference ratios when measured in a single scanner, single protocol setup.
MATERIALS AND METHODS: 284 consecutive patients who underwent 3 T MRI on a single scanner followed by MRI-transrectal ultrasound fusion biopsy were included. A board-certified radiologist retrospectively reviewed all MRIs blinded to clinical information and placed regions of interest (ROI) on all focal lesions and the following reference regions: normal-appearing peripheral zone (PZNL) and transition zone (TZNL), the urinary bladder (BLA), and right and left internal obturator muscle (RIOM, LIOM). ROI-based mean ADC and ADC ratios to the reference regions were compared regarding their ability to predict the aggressiveness of prostate cancer. Spearman's rank correlation coefficient was used to estimate the correlation between ADC parameters, Gleason score (GS) and ADC ratios. The primary endpoint was presence of sPC, defined as a GS ≥ 3 + 4. Univariable and multivariable logistic regression models were constructed to predict sPC. Receiver operating characteristics curves (ROC) were used for visualization; DeLong test was used to evaluate the differences of the area under the curve (AUC). Bias-corrected AUC values and corresponding 95 %-CI were calculated using bootstrapping with 100 bootstrap samples.
RESULTS: After exclusion of patients who received prior treatment, 259 patients were included in the final cohort of which 220 harbored 351 MR lesions. Mean ADC and ADC ratios demonstrated a negative correlation with the GS. Mean ADC had the strongest correlation with ρ of -0.34, followed by ADCratioPZNL (ρ=-0.32). All ADC parameters except ADCratioLIOM (p = 0.07) were associated with sPC p<0.05). Mean ADC and ADCratioPZNL had the highest ROC AUC of all parameters (0.68). Multivariable models with mean ADC improve predictive performance.
CONCLUSIONS: A highly standardized single-scanner mean ADC measurement could not be improved upon using any of the single ADC ratio parameters or combinations of these parameters in predicting the aggressiveness of prostate cancer.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Apparent diffusion coefficient; Gleason score; Multiparametric MRI; Prostate cancer

Mesh:

Year:  2021        PMID: 33482592     DOI: 10.1016/j.ejrad.2021.109538

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.

Authors:  Young Sub Lee; Moon Hyung Choi; Young Joon Lee; Dongyeob Han; Dong-Hyun Kim
Journal:  Br J Radiol       Date:  2021-08-20       Impact factor: 3.039

2.  Non-timely clinically applicable ADC ratio in prostate mpMRI: a comparison with fusion biopsy results.

Authors:  Zeno Falaschi; Stefano Tricca; Silvia Attanasio; Michele Billia; Chiara Airoldi; Ilaria Percivale; Simone Bor; Davide Perri; Alessandro Volpe; Alessandro Carriero
Journal:  Abdom Radiol (NY)       Date:  2022-08-09

3.  A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer.

Authors:  Björn J Langbein; Filip Szczepankiewicz; Carl-Fredrik Westin; Camden Bay; Stephan E Maier; Adam S Kibel; Clare M Tempany; Fiona M Fennessy
Journal:  Invest Radiol       Date:  2021-12-01       Impact factor: 6.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.